Glaucin (Dragee, Syrup) Instructions for Use
ATC Code
R05DB (Other antitussive drugs)
Active Substance
Glaucine (BP British Pharmacopoeia)
Clinical-Pharmacological Group
Antitussive drug
Pharmacotherapeutic Group
Central antitussive agent
Pharmacological Action
Antitussive agent of central action. An alkaloid of the plant Yellow Horned Poppy (Glaucium flavum).
Unlike codeine, it does not depress the respiratory center, does not suppress intestinal motor activity; with prolonged use, it does not cause drug dependence or habituation.
It has adrenolytic properties and may cause a decrease in blood pressure.
Indications
- Cough of various etiologies, including in infectious and inflammatory diseases of the upper respiratory tract, bronchi and lungs.
- Use in bronchial asthma, pleurisy, whooping cough, tuberculosis, and lung cancer.
ICD codes
| ICD-10 code | Indication |
| A15 | Respiratory tuberculosis, bacteriologically and histologically confirmed |
| A37 | Whooping cough |
| C34 | Malignant neoplasm of bronchus and lung |
| J04 | Acute laryngitis and tracheitis |
| J15 | Bacterial pneumonia, not elsewhere classified |
| J20 | Acute bronchitis |
| J37 | Chronic laryngitis and laryngotracheitis |
| J42 | Unspecified chronic bronchitis |
| J45 | Asthma |
| R05 | Cough |
| R09.1 | Pleurisy |
| ICD-11 code | Indication |
| 1B10.0 | Respiratory tuberculosis, bacteriologically or histologically confirmed |
| 1C12.Z | Whooping cough, unspecified |
| 2C25.Z | Malignant neoplasms of bronchus or lung, unspecified |
| CA05 | Acute laryngitis or tracheitis |
| CA0G | Chronic laryngitis or laryngotracheitis |
| CA20.1Z | Chronic bronchitis, unspecified |
| CA23 | Asthma |
| CA40.0Z | Bacterial pneumonia, unspecified |
| CA42.Z | Acute bronchitis, unspecified |
| MD12 | Cough |
| MD31 | Pleurisy |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
For adults, administer a single dose of 40 mg orally 2-3 times/day to suppress cough. To control severe night cough, administer a single dose of 80 mg at bedtime. Do not exceed the maximum daily dose of 200 mg.
For children over 4 years of age, administer a single dose of 10 mg orally 2-3 times/day. Administer all doses after meals to improve tolerability.
Adverse Reactions
Adverse reactions are infrequent and typically associated with higher doses. Dizziness, weakness, nausea, and decreased blood pressure may occur, particularly after a single 80 mg dose.
Monitor for potential allergic reactions. Discontinue use if severe adverse reactions develop.
Contraindications
- Do not use in patients with known hypersensitivity to the active substance or any excipient.
- Contraindicated in arterial hypotension and in the acute phase of myocardial infarction due to adrenolytic properties.
- Avoid use in conditions with significant hypersecretion of sputum where cough suppression is undesirable.
Pediatric Use
Not recommended for use in children under 4 years of age.
Special Precautions
Not recommended for use in children under 4 years of age.
Drug Interactions
This agent can be administered in combination with ephedrine hydrochloride, citric acid, and basil oil amber without known significant pharmacokinetic interactions.
Exercise caution with concomitant use of other centrally acting drugs or antihypertensive agents due to potential additive effects on blood pressure and the central nervous system.
Overdose
Symptoms of overdose may include pronounced dizziness, severe hypotension, marked weakness, and nausea.
In case of overdose, implement symptomatic and supportive measures, with particular attention to managing blood pressure. There is no specific antidote.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Dragees 40 mg: 20 pcs.
Marketing Authorization Holder
Jaka-80 (Macedonia)
Dosage Form
| Glaucine | Dragees 40 mg: 20 pcs. |
Dosage Form, Packaging, and Composition
| Dragee | 1 dragee |
| Glaucine phosphate | 40 mg |
20 pcs. – blister packs (1) – cardboard packs.
Syrup 40 mg/15 ml: bottle 150 ml
Marketing Authorization Holder
Jaka-80 (Macedonia)
Dosage Form
| Glaucine | Syrup 40 mg/15 ml: bottle 150 ml |
Dosage Form, Packaging, and Composition
| Syrup | 15 ml |
| Glaucine phosphate | 40 mg |
150 ml – dark glass bottles (1) – cardboard packs.
Syrup (for children) 5 mg/5 ml: bottle 60 ml
Marketing Authorization Holder
Jaka-80 (Macedonia)
Dosage Form
| Glaucine | Syrup (for children) 5 mg/5 ml: bottle 60 ml |
Dosage Form, Packaging, and Composition
| Syrup for children | 5 ml |
| Glaucine phosphate | 5 mg |
60 ml – dark glass bottles (1) – cardboard packs.
